

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)



(10) International Publication Number
WO 2021/186245 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/18 (2017.01)
A61K 39/00 (2006.01) A61K 47/26 (2006.01)
A61K 47/12 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2021/000155

(22) International Filing Date:

19 March 2021 (19.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/992,746 20 March 2020 (20.03.2020) US
63/027,263 19 May 2020 (19.05.2020) US

(71) Applicant: EISAI R&D MANAGEMENT CO., LTD.

[JP/JP]; 6-10, Koishikawa, 4-chome, Bunkyo-ku, Tokyo 112-8088 (JP).

(72) Inventors: YOSHIDA, Nobuo; c/o Eisai Co., Ltd., 4-6-10

Koishikawa, Bunkyo-ku, Tokyo 112-8088 (JP). SAKU-RAMOTO, Naomi; c/o Eisai Co., Ltd., Kawashima Industrial Complex, 1 Kawashimatake-haya-machi, Kakamigahara-shi, Gifu 501-6195 (JP). SAKAGUCHI, Takahisa; c/o Eisai Co., Ltd., Kawashima Industrial Complex, 1 Kawashimatake-haya-machi, Kakamigahara-shi, Gifu 501-6195 (JP). KITO, Hirokazu; c/o Eisai Co., Ltd., Kawashima Industrial Complex, 1 Kawashimatake-haya-machi, Kakamigahara-shi, Gifu 501-6195 (JP). OZAWA, Takahiro; c/o Eisai Co., Ltd., Kawashima Industrial Complex, 1 Kawashimatake-haya-machi, Kakamigahara-shi, Gifu 501-6195 (JP). JOSHI, Anjali; 208 Capistrano Drive, Cary, North Carolina 27519 (US). HSU, Yung Yueh; 109 Aberdeen Drive, Carlisle, Massachusetts 01741 (US). SOUILLAC, Pierre; 116 Sylvester Avenue, Winchester, Massachusetts 01890 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HIGH CONCENTRATION ANTI-A β PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are aqueous pharmaceutical formulations comprising high concentrations of an isolated anti-A β protofibril antibody or a fragment thereof that binds to human A β protofibrils, such as BAN2401, arginine, polysorbate 80, and a pharmaceutically acceptable buffer.

WO 2021/186245 A1